Adrenal fatigue is an increasingly common yet sometimes controversial diagnosis used to indicate depletion of the adrenal glands. Cortisol is a hormone released by the adrenals for use in the regulation of blood pressure. In response to stress, the adrenals release greater amounts of cortisol. Adrenal fatigue is thought to occur when the adrenals have become overtaxed by excess cortisol release and can no longer produce levels of cortisol necessary for optimal body function. Common symptoms of adrenal fatigue include fatigue, particularly upon waking, with intermittent “crashes” throughout the day, poor stress response and mood regulation, cravings for salty and sweet foods and many more.
The global adrenal fatigue market size is predicted to reach over USD 1,137 million by 2028. This can be ascribed to the increase in awareness regarding timely diagnosis of congenital disorders. Increasing risk of trauma cases due to a number of factors such as road injuries, war-related trauma, other accidents, and increasing global disease burden, acquired adrenal insufficiency is anticipated to grow at a faster pace during the forecast period. Besides, demand for development of newer and technologically enhanced products is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the market are investing in research & development programs in order to develop new drugs, which is also the key factor driving the market growth for adrenal fatigue.
However, poor reimbursement, high cost of treatment, and various side effects associated with drugs are hampering the market growth. Furthermore, the adrenal fatigue market is growing due to technological advancements and increasing R&D activities for the drugs development and rise in number of end-use applications, which are likely to provide lucrative development opportunities for the adrenal fatigue market in the forthcoming years.
Adrenal Fatigue Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 1,137 million|
|Growth Rate||CAGR of 7.9% during 2021-2028|
|Segment Covered||Indication, Source, Treatment, Distribution Channel, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||Pfizer, Inc., Mylan Pharmaceuticals, Inc., Novartis International AG, Mallinckrodt Pharmaceuticals, Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company and Sanofi.|
Key Segments of the Global Adrenal Fatigue Market
Indication Overview, 2019-2028 (USD Million)
Source Overview, 2019-2028 (USD Million)
Treatment Overview, 2019-2028 (USD Million)
Distribution Channel Overview, 2019-2028 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Overview, 2019-2028 (USD Million)
- Rest of Europe
- Rest of Asia-Pacific
Middle East and Africa
- South Africa
- Rest of Middle East and Africa
- Rest of South America
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global adrenal fatigue market. Benchmark yourself against the rest of the market.
- Ensure you remain competitive as innovations by existing key players to boost the market.
What does the report include?
- The study on the global adrenal fatigue market includes qualitative factors such as drivers, restraints, and opportunities
- The study covers the competitive landscape of existing/prospective players in the adrenal fatigue industry and their strategic initiatives for product development.
- The study covers a qualitative and quantitative analysis of the market segmented based on Indication, Source, Treatment, and Distribution Channel. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments.
Who should buy this report?
- This study is suitable for industry participants and stakeholders in the global adrenal fatigue market. The report will benefit Every stakeholder involved in the adrenal fatigue market.
- Managers within the adrenal fatigue industry looking to publish recent and forecasted statistics about the global adrenal fatigue market.
- Government organizations, regulatory authorities, policymakers, and organizations looking for investments in trends of the global adrenal fatigue market.
- Analysts, researchers, educators, strategy managers, and government institutions looking for insights into the market to determine future strategies.
Adrenal fatigue is a symptom-based syndrome tightly linked to chronic stress — both physical and emotional. Being under stress day after day, week after week, forces the adrenal glands to work overtime pumping out the hormone cortisol at emergency levels.
Adrenal fatigue develops over time in response to chronic stress. The longer it goes on, the more likely it develops symptoms. Some of the more common symptoms of adrenal fatigue include exhaustion, insomnia, anxiety, intense irritability, fuzzy thinking and weight gain. Adrenal fatigue and adrenal stress can create a long and varied list of symptoms because these issues are often intertwined with other hormonal imbalances.
Furthermore, women in their 40s and beyond who find themselves tired, tense and stressed-out usually suspect their symptoms are caused by perimenopause. But even when women are on the cusp of menopause, adrenal stress can be the driving force behind more difficult symptoms. The increasing awareness about women’s health is also propelling the demand in the global adrenal fatigue market.
The market is consolidated as several major market players currently hold the major market share. However, the market is expected to become fragmented in the forthcoming years as several new market players are emerging from developing countries such as India, Japan, China, and other countries.
Based on the Indication segment, the market is bifurcated into Primary, Secondary and Tertiary. In 2020, secondary segment accumulated the maximum market share and it is likely to continue its dominance throughout the forecast years. It can be caused by an insult or injury to the hypothalamus of the pituitary gland. In this case, the patients require glucocorticoid replacement such as prednisone or hydrocortisone.
Based on the Source, the market is segmented into Congenital, and Acquired. The Congenital segment seized the maximum market share in 2020 and it is likely to maintain its place throughout the forecast years. The growth of this segment is largely ascribed to the prevalence of adrenal fatigue in majority of the population from birth.
Based on the Treatment, the market is segmented into Glucocorticoids, Corticotropin and others. The Glucocorticoids segment seized the maximum market share in 2020 and it is likely to maintain its place throughout the forecast years. The growth of this segment is largely ascribed to the growing demand for Glucocorticoids as it is widely used to cure patients with secondary adrenal fatigue. Also, the demand for Glucocorticoids adrenal fatigue is increasing in many medical applications.
Distribution Channel Segment
Based on the Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacy segment gathered the major market share in 2020 and it is likely to continue its dominance throughout the forecast years owing to the increasing patients visits to look for professional help for their degrading health. However, the rising patient preference to buy products from nearby pharmacies on a regular basis is responsible for the growth of the retail pharmacies segment.
The Asia Pacific region is likely to account for the maximum market contribution during the forecast years. The domination of this region is largely ascribed to the improving health care infrastructure, rising awareness about timely diagnosis of underlying disorders such as adrenal insufficiency, and large patient population. Increase in public and private health care expenditure in countries such as China and India is expected to attract manufacturers toward these markets.
The major players of the global adrenal fatigue market are Pfizer, Inc., Mylan Pharmaceuticals, Inc., Novartis International AG, Mallinckrodt Pharmaceuticals, Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company and Sanofi. Renowned companies are escalating healthcare spending, increasing sales of prescription drugs, rising spending on medicines and growing market for orphan drugs. Besides, the previously recognized as well as new market players are approaching the market with advanced and new strategic services and solutions and to remain competitive in the global market.